Vaccine Induced Antibodies Target Articles & Analysis
40 news found
Protheragen is proud to release the launch of its comprehensive vaccine development solutions tailored to advance research and development in the field of infectious diseases. This strategic initiative aims to accelerate the creation of effective vaccines to combat emerging and re-emerging infectious threats. Infectious diseases are disorders caused by organisms — such as bacteria, ...
Ace Therapeutics is a preclinical contract research provider engaged in metabolic disorders, infectious diseases and parasites, neurological disorders, ophthalmic diseases, gastrointestinal disorders, and immune system diseases. With the rise of antibiotic-resistant bacteria posing a significant threat to global public health, Ace Therapeutics announces its new vaccine development services to ...
BOC Sciences, a tech-driven company, is delighted to announce that its team will be participating in the prestigious Drug Discovery Chemistry (DDC) conference in April 2024. The company will be situated at booth #117, showcasing its quality chemical materials and advanced technologies. DDC is an annual event that gathers researchers, scientists, and experts from across the globe who are involved ...
IRVINE, Calif. – OCT. 4, 2022 – AIVITA Biomedical, Inc., a biotech company specializing in innovative cell applications, today announced that the Journal of Oncology Research and Therapy has published data from its completed Phase 2 glioblastoma (GBM) study which demonstrates enhanced progression-free survival (PFS). The publication, titled “Enhanced Progression-Free Survival in ...
Ziphius Vaccines is developing a proprietary self-amplifying mRNA technology platform combined with innovative lipid formulations for delivery. saRNA or replicon RNA has the advantage of having self-replicating features, as the saRNA molecule encodes a viral RNA replicase in addition to the sequence of the protein(s) of interest. This mechanism leads to enhanced and prolonged protein ...
Ziphius Vaccines (the “Company” or “Ziphius”), a biopharmaceutical company developing transformative self-amplifying RNA (saRNA) based medicinal products for vaccine and therapeutic applications, and University of Antwerp today announce that they have entered into a collaboration agreement to research and develop a dynamic lipid library for optimized delivery systems ...
Vaxxinity, Inc. (Nasdaq: VAXX), a company pioneering the development of a new class of immunotherapeutic vaccines, today announced that UB-311, an anti-amyloid beta immunotherapeutic vaccine, has been granted Fast Track designation by the U.S. Food and Drug Administration (FDA) for the treatment of Alzheimer’s disease. “We are excited that the FDA has granted UB-311 Fast Track ...
ByVaxxinit
VITRUVIAN BioMedical, Inc. (“VITRUVIAN”), a biotechnology company, today announced obtaining the Exclusive License for a new Therapeutic Vaccine for Alzheimer’s Disease (AD) from Dr. Yoh Matsumoto from the Immunotherapy Development Inc. in Saitama, Japan and the Tokyo Metropolitan Institute of Medical Science, Tokyo, Japan. The AD Vaccine, YM7555, is a DNA Vaccine that targets ...
The paper entitled “A dual-antigen self-amplifying RNA SARS-CoV-2 vaccine induces potent humoral and cellular immune responses and protects against SARS-CoV-2 variants through T cell-mediated immunity” shows that Ziphius’ multi-antigenic self-amplifying RNA COVID-19 vaccine candidate induces a potent humoral and ...
Vaxxinity’s investigational UB-312 vaccine candidate targets pathological forms of alpha-synuclein (aSyn) to treat PD and other conditions such as dementia with Lewy bodies (DLB) and multiple system atrophy (MSA). ...
ByVaxxinit
IRVINE, Calif. – Apr. 5, 2022 – AIVITA Biomedical, Inc., a biotech company specializing in innovative stem cell applications, today announced the appointment of distinguished neuroscientist and industry specialist H. Christian Fibiger, Ph.D. to its board of directors. Dr. Fibiger served as vice president and global head of neuroscience at Amgen, the world’s largest ...
About Scancell Scancell is developing novel immunotherapies for the treatment of cancer based on its technology platforms, ImmunoBody®, Moditope® and AvidiMabTM, with four products in multiple cancer indications, development of a vaccine for COVID-19 and a growing portfolio of novel anti-TaG monoclonal antibodies. ImmunoBody® ...
ByScancell
IRVINE, Calif. – Mar. 9, 2022 – AIVITA Biomedical, Inc., a biotech company specializing in innovative stem cell applications, today announced that chairman and CEO Dr. Hans S. Keirstead will deliver an opening keynote at the World Immunotherapy Congress, a submeeting of the Festival of Biologics taking place March 9-11 in San Diego. Dr. Keirstead is scheduled to deliver an opening ...
Oral insulin program continues to advance with topline efficacy data expected in H2 2022 Significant value creation opportunities through oral COVID-19 vaccine program and partnerships Well positioned to capitalize on opportunities with strong cash balance of ~$174 million as of December 3, 2021 Oramed Pharmaceuticals Inc. (NASDAQ: ORMP) (TASE: ORMP), a clinical-stage pharmaceutical ...
Expands Pfizer’s access to lipid nanoparticle (LNP) formulation technology, offering a strong strategic fit with Pfizer’s mRNA strategy Pfizer gains option to license Acuitas’ LNP technology for up to 10 targets for vaccine or therapeutic development Pfizer Inc. (NYSE: PFE) and Acuitas Therapeutics, a company focused on developing lipid nanoparticle (LNP) delivery systems ...
Initial pre-purchase of 10 million doses of oral vaccines with a potential deal for further orders worth hundreds of millions of dollars Prospective patient population of approximately 660 million throughout the Association of Southeast Asian Nations Oramed Pharmaceuticals Inc. (Nasdaq: ORMP) (TASE: ORMP) (www.oramed.com), a clinical-stage pharmaceutical company focused on the development of ...
Oravax’s oral vaccine targets three surface proteins, making it potentially more effective against current and future variants Oravax’s oral vaccine should offer critical advantages, including logistics, distribution and delivery in less vaccinated regions, including Africa Oramed Pharmaceuticals Inc. (Nasdaq: ORMP) (TASE: ORMP) (www.oramed.com), a clinical-stage pharmaceutical ...
The virtual 34th International Papillomavirus Conference took place last week, from November 15-19. The conference’s theme this year was: ‘Research and education for HPV elimination’. Jeanettes E-Poster ‘A Candidate Broadly Protective HPV-Vaccine Targeting the L2 Minor Protein Demonstrates Promising Results in a Clinical Phase I Trial’ was selected for the ...
Oxford, UK, 16 November 2021: SpyBiotech, a biotechnology company with a novel vaccine platform technology targeting infectious diseases, cancer and chronic diseases, today announces the appointment of Simon Jones as VP of Finance and Operations, and the expansion of its scientific team with four new hires. Simon takes up the permanent position of VP Finance and Operations from Vien Phan, who ...
IRVINE, Calif. – Nov. 16, 2021 – AIVITA Biomedical, Inc., a biotech company specializing in innovative stem cell applications, today announced that chairman and CEO Dr. Hans S. Keirstead will deliver a keynote at the Vaccine World Asia Congress. The Singapore-based congress is being held virtually November 17-18. Dr. Keirstead’s speaking details are as follows: Keynote: A Fully ...